Friday, May 3, 2013

FDA Approves Invokana to Treat Type 2 Diabetes

In continuation of my update on canagliflozin/Invokana...

We know that, Canagliflozin (Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. In March 2013, canagliflozin became the first SGLT2 inhibitor to be approved in the United States...

FDA Approves Invokana to Treat Type 2 Diabetes

2 comments:

jelly andrews said...

It is nice to know this information. But what will be the side effects of this drug? What will be the things that need to be considered when taking this drug?

dr.umesh l said...


Side effects : (Reported during studies): cardiovascular problems have been noted with this class of drugs along with canagliflozin. During one trial with canagliflozin there was an increased risk of stroke the individual MACE-plus component of stroke, the hazard ratio was non-significantly elevated, at 1.5 (95% CI, 0.8 - 2.6). Also the CANVAS trial, also with canagliflozin, showed some concern about cardiovascular events. Although final results from the CANVAS trial are not expected until 2015, during the first 30 days after randomization in CANVAS, there were 13 cardiovascular events in the patients receiving canagliflozin (0.45%) vs 1 in patients receiving placebo (0.07%). The hazard ratio of 6.5 was not significant because of the small number of events (95% confidence interval, 0.85 - 49.66). [6] Furthermore Johnson and Johnson also reported to investors that canagliflozin increased LDL cholesterol, urinary tract infections, genital mycotic infections, and was associated increased urination and episodes of hypotension and hypoglycemia. The same report did show that the drug decreased weight by a 1.9 - 3% (using the confidence intervals of the 2 studies sited) as well as decreased hemoglobin AIC by 0.57-0.70%, reduced both systolic and diastolic blood pressures and raised HDL cholesterol...

More : http://en.wikipedia.org/wiki/Canagliflozin